share_log

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60

Benzinga ·  May 8 11:54

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $58 to $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment